[{"orgOrder":0,"company":"Vensica Medical","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Incobotulinumtoxin A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vensica Medical","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vensica Medical \/ Israel Biotech Fund","highestDevelopmentStatusID":"14","companyTruncated":"Vensica Medical \/ Israel Biotech Fund"}]

Find Clinical Drug Pipeline Developments & Deals by Vensica Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The fund will support the company's mid-stage clinical trials for its revolutionary treatment of overactive bladder using Xeomin (Incobotulinumtoxin A), delivered through a needle-free device.

                          Brand Name : Xeomin

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Incobotulinumtoxin A

                          Therapeutic Area : Urology

                          Highest Development Status : Phase I

                          Sponsor : Israel Biotech Fund

                          Deal Size : $11.0 million

                          Deal Type : Funding

                          blank